Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

April 4, 2014 updated by: Boehringer Ingelheim

Post Marketing Surveillance on Long Drug Use of Micombi Combination Tablets in Patients With Hypertension

The survey is conducted to collect safety and effectiveness information in Hypertensive patients treated with Micombi Tablets on the long term use in daily clinical settings in Japan.

Study Overview

Status

Completed

Conditions

Hypertension

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

1452

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Japan
- - Ageo, Japan
    - Boehringer Ingelheim Investigational Site 111
  - Aisho-cho, Japan
    - Boehringer Ingelheim Investigational Site 209
  - Aizubange-machi, Japan
    - Boehringer Ingelheim Investigational Site 22
  - Akashi, Japan
    - Boehringer Ingelheim Investigational Site 234
  - Akiruno, Japan
    - Boehringer Ingelheim Investigational Site 78
  - Akishima, Japan
    - Boehringer Ingelheim Investigational Site 79
  - Ako, Japan
    - Boehringer Ingelheim Investigational Site 235
  - Akune, Japan
    - Boehringer Ingelheim Investigational Site 288
  - Amagasaki, Japan
    - Boehringer Ingelheim Investigational Site 236
  - Amagasaki, Japan
    - Boehringer Ingelheim Investigational Site 237
  - Anan, Japan
    - Boehringer Ingelheim Investigational Site 280
  - Anjo, Japan
    - Boehringer Ingelheim Investigational Site 160
  - Asahikawa, Japan
    - Boehringer Ingelheim Investigational Site 1
  - Ashikaga, Japan
    - Boehringer Ingelheim Investigational Site 51
  - Atsugi, Japan
    - Boehringer Ingelheim Investigational Site 140
  - Azumino, Japan
    - Boehringer Ingelheim Investigational Site 58
  - Chiba, Japan
    - Boehringer Ingelheim Investigational Site 128
  - Chiba, Japan
    - Boehringer Ingelheim Investigational Site 138
  - Chigasaki, Japan
    - Boehringer Ingelheim Investigational Site 141
  - Chikujo-machi, Japan
    - Boehringer Ingelheim Investigational Site 299
  - Chikusei, Japan
    - Boehringer Ingelheim Investigational Site 44
  - Chofu, Japan
    - Boehringer Ingelheim Investigational Site 80
  - Ebino, Japan
    - Boehringer Ingelheim Investigational Site 311
  - Fuchu, Japan
    - Boehringer Ingelheim Investigational Site 257
  - Fuefuki, Japan
    - Boehringer Ingelheim Investigational Site 71
  - Fujieda, Japan
    - Boehringer Ingelheim Investigational Site 179
  - Fujiidera, Japan
    - Boehringer Ingelheim Investigational Site 211
  - Fukaya, Japan
    - Boehringer Ingelheim Investigational Site 112
  - Fukui, Japan
    - Boehringer Ingelheim Investigational Site 206
  - Fukuoka, Japan
    - Boehringer Ingelheim Investigational Site 300
  - Fukuoka, Japan
    - Boehringer Ingelheim Investigational Site 301
  - Fukuoka, Japan
    - Boehringer Ingelheim Investigational Site 302
  - Fukuoka, Japan
    - Boehringer Ingelheim Investigational Site 303
  - Fukuroi, Japan
    - Boehringer Ingelheim Investigational Site 180
  - Fukushima, Japan
    - Boehringer Ingelheim Investigational Site 23
  - Fukuyama, Japan
    - Boehringer Ingelheim Investigational Site 258
  - Funabashi, Japan
    - Boehringer Ingelheim Investigational Site 129
  - Gifu, Japan
    - Boehringer Ingelheim Investigational Site 174
  - Gifu, Japan
    - Boehringer Ingelheim Investigational Site 175
  - Gonohe-machi, Japan
    - Boehringer Ingelheim Investigational Site 42
  - Gyoda, Japan
    - Boehringer Ingelheim Investigational Site 113
  - Habikino, Japan
    - Boehringer Ingelheim Investigational Site 212
  - Hachioji, Japan
    - Boehringer Ingelheim Investigational Site 81
  - Hachioji, Japan
    - Boehringer Ingelheim Investigational Site 82
  - Hakusan, Japan
    - Boehringer Ingelheim Investigational Site 193
  - Hamamatsu, Japan
    - Boehringer Ingelheim Investigational Site 181
  - Hashimoto, Japan
    - Boehringer Ingelheim Investigational Site 247
  - Hatano, Japan
    - Boehringer Ingelheim Investigational Site 142
  - Hatsukaichi, Japan
    - Boehringer Ingelheim Investigational Site 259
  - Higashikagawa, Japan
    - Boehringer Ingelheim Investigational Site 276
  - Higashikurume, Japan
    - Boehringer Ingelheim Investigational Site 83
  - Higashimatsuyama, Japan
    - Boehringer Ingelheim Investigational Site 114
  - Higashiosaka, Japan
    - Boehringer Ingelheim Investigational Site 213
  - Hino, Japan
    - Boehringer Ingelheim Investigational Site 84
  - Hirosaki, Japan
    - Boehringer Ingelheim Investigational Site 43
  - Hiroshima, Japan
    - Boehringer Ingelheim Investigational Site 260
  - Hiroshima, Japan
    - Boehringer Ingelheim Investigational Site 261
  - Hiroshima, Japan
    - Boehringer Ingelheim Investigational Site 262
  - Hiroshima, Japan
    - Boehringer Ingelheim Investigational Site 263
  - Hitachinaka, Japan
    - Boehringer Ingelheim Investigational Site 45
  - Hofu, Japan
    - Boehringer Ingelheim Investigational Site 266
  - Hokuto, Japan
    - Boehringer Ingelheim Investigational Site 72
  - Ibara, Japan
    - Boehringer Ingelheim Investigational Site 249
  - Ibaraki, Japan
    - Boehringer Ingelheim Investigational Site 214
  - Ibaraki, Japan
    - Boehringer Ingelheim Investigational Site 215
  - Ichikawa, Japan
    - Boehringer Ingelheim Investigational Site 130
  - Ichinomiya, Japan
    - Boehringer Ingelheim Investigational Site 161
  - Ichinoseki, Japan
    - Boehringer Ingelheim Investigational Site 18
  - Ichinoseki, Japan
    - Boehringer Ingelheim Investigational Site 19
  - Ina, Japan
    - Boehringer Ingelheim Investigational Site 59
  - Isa, Japan
    - Boehringer Ingelheim Investigational Site 289
  - Ise, Japan
    - Boehringer Ingelheim Investigational Site 187
  - Isesaki, Japan
    - Boehringer Ingelheim Investigational Site 74
  - Ito, Japan
    - Boehringer Ingelheim Investigational Site 182
  - Iwafune-machi, Japan
    - Boehringer Ingelheim Investigational Site 52
  - Iwaki, Japan
    - Boehringer Ingelheim Investigational Site 24
  - Iwakura, Japan
    - Boehringer Ingelheim Investigational Site 162
  - Izumisano, Japan
    - Boehringer Ingelheim Investigational Site 216
  - Kaga, Japan
    - Boehringer Ingelheim Investigational Site 194
  - Kagoshima, Japan
    - Boehringer Ingelheim Investigational Site 290
  - Kai, Japan
    - Boehringer Ingelheim Investigational Site 73
  - Kanazawa, Japan
    - Boehringer Ingelheim Investigational Site 195
  - Kanuma, Japan
    - Boehringer Ingelheim Investigational Site 53
  - Kariya, Japan
    - Boehringer Ingelheim Investigational Site 163
  - Kasai, Japan
    - Boehringer Ingelheim Investigational Site 238
  - Kasugai, Japan
    - Boehringer Ingelheim Investigational Site 164
  - Kasukabe, Japan
    - Boehringer Ingelheim Investigational Site 115
  - Kawachinagano, Japan
    - Boehringer Ingelheim Investigational Site 217
  - Kawaguchi, Japan
    - Boehringer Ingelheim Investigational Site 116
  - Kawaguchi, Japan
    - Boehringer Ingelheim Investigational Site 117
  - Kawai-cho, Japan
    - Boehringer Ingelheim Investigational Site 231
  - Kawasaki, Japan
    - Boehringer Ingelheim Investigational Site 143
  - Kawasaki, Japan
    - Boehringer Ingelheim Investigational Site 144
  - Kawasaki, Japan
    - Boehringer Ingelheim Investigational Site 145
  - Kawatana-cho, Japan
    - Boehringer Ingelheim Investigational Site 296
  - Kazuno, Japan
    - Boehringer Ingelheim Investigational Site 40
  - Kesennuma, Japan
    - Boehringer Ingelheim Investigational Site 29
  - Kisarazu, Japan
    - Boehringer Ingelheim Investigational Site 131
  - Kitahiroshima, Japan
    - Boehringer Ingelheim Investigational Site 2
  - Kitakyushu, Japan
    - Boehringer Ingelheim Investigational Site 304
  - Kitakyushu, Japan
    - Boehringer Ingelheim Investigational Site 305
  - Kitakyusyu, Japan
    - Boehringer Ingelheim Investigational Site 306
  - Kobe, Japan
    - Boehringer Ingelheim Investigational Site 239
  - Kobe, Japan
    - Boehringer Ingelheim Investigational Site 240
  - Kobe, Japan
    - Boehringer Ingelheim Investigational Site 241
  - Kobe, Japan
    - Boehringer Ingelheim Investigational Site 242
  - Koriyama, Japan
    - Boehringer Ingelheim Investigational Site 25
  - Koshigaya, Japan
    - Boehringer Ingelheim Investigational Site 118
  - Kotohira, Japan
    - Boehringer Ingelheim Investigational Site 277
  - Kumagaya, Japan
    - Boehringer Ingelheim Investigational Site 119
  - Kumamoto, Japan
    - Boehringer Ingelheim Investigational Site 291
  - Kumamoto, Japan
    - Boehringer Ingelheim Investigational Site 292
  - Kunisaki, Japan
    - Boehringer Ingelheim Investigational Site 284
  - Kurashiki, Japan
    - Boehringer Ingelheim Investigational Site 250
  - Kure, Japan
    - Boehringer Ingelheim Investigational Site 264
  - Kure, Japan
    - Boehringer Ingelheim Investigational Site 265
  - Kusu-machi, Japan
    - Boehringer Ingelheim Investigational Site 285
  - Kyoto, Japan
    - Boehringer Ingelheim Investigational Site 197
  - Kyoto, Japan
    - Boehringer Ingelheim Investigational Site 198
  - Kyoto, Japan
    - Boehringer Ingelheim Investigational Site 199
  - Kyoto, Japan
    - Boehringer Ingelheim Investigational Site 200
  - Machida, Japan
    - Boehringer Ingelheim Investigational Site 85
  - Maebaru, Japan
    - Boehringer Ingelheim Investigational Site 307
  - Matsuda-machi, Japan
    - Boehringer Ingelheim Investigational Site 146
  - Matsudo, Japan
    - Boehringer Ingelheim Investigational Site 132
  - Matsumoto, Japan
    - Boehringer Ingelheim Investigational Site 60
  - Matsumoto, Japan
    - Boehringer Ingelheim Investigational Site 61
  - Matsuyama, Japan
    - Boehringer Ingelheim Investigational Site 272
  - Matsuyama, Japan
    - Boehringer Ingelheim Investigational Site 273
  - Matsuzaka, Japan
    - Boehringer Ingelheim Investigational Site 188
  - Minamata, Japan
    - Boehringer Ingelheim Investigational Site 293
  - Minamisanriku-cho, Japan
    - Boehringer Ingelheim Investigational Site 30
  - Minoo, Japan
    - Boehringer Ingelheim Investigational Site 218
  - Mito, Japan
    - Boehringer Ingelheim Investigational Site 46
  - Miyazaki, Japan
    - Boehringer Ingelheim Investigational Site 312
  - Mobara, Japan
    - Boehringer Ingelheim Investigational Site 133
  - Morioka, Japan
    - Boehringer Ingelheim Investigational Site 20
  - Motomiya, Japan
    - Boehringer Ingelheim Investigational Site 26
  - Mukawa-cho, Japan
    - Boehringer Ingelheim Investigational Site 3
  - Musashino, Japan
    - Boehringer Ingelheim Investigational Site 86
  - Nagano, Japan
    - Boehringer Ingelheim Investigational Site 62
  - Nagano, Japan
    - Boehringer Ingelheim Investigational Site 63
  - Nagasaki, Japan
    - Boehringer Ingelheim Investigational Site 297
  - Nagoya, Japan
    - Boehringer Ingelheim Investigational Site 165
  - Nagoya, Japan
    - Boehringer Ingelheim Investigational Site 166
  - Nagoya, Japan
    - Boehringer Ingelheim Investigational Site 167
  - Nagoya, Japan
    - Boehringer Ingelheim Investigational Site 168
  - Nagoya, Japan
    - Boehringer Ingelheim Investigational Site 192
  - Naha, Japan
    - Boehringer Ingelheim Investigational Site 314
  - Nakadori, Japan
    - Boehringer Ingelheim Investigational Site 41
  - Nakagawa-machi, Japan
    - Boehringer Ingelheim Investigational Site 54
  - Nakatsugawa, Japan
    - Boehringer Ingelheim Investigational Site 176
  - Nanao, Japan
    - Boehringer Ingelheim Investigational Site 196
  - Nankoku, Japan
    - Boehringer Ingelheim Investigational Site 278
  - Nara, Japan
    - Boehringer Ingelheim Investigational Site 232
  - Natori, Japan
    - Boehringer Ingelheim Investigational Site 31
  - Nayoro, Japan
    - Boehringer Ingelheim Investigational Site 4
  - Nichinan, Japan
    - Boehringer Ingelheim Investigational Site 313
  - Niigata, Japan
    - Boehringer Ingelheim Investigational Site 65
  - Niigata, Japan
    - Boehringer Ingelheim Investigational Site 66
  - Ninomiya-machi, Japan
    - Boehringer Ingelheim Investigational Site 147
  - Nishinomiya, Japan
    - Boehringer Ingelheim Investigational Site 243
  - Nishinomiya, Japan
    - Boehringer Ingelheim Investigational Site 244
  - Nishio, Japan
    - Boehringer Ingelheim Investigational Site 169
  - Nishitokyo, Japan
    - Boehringer Ingelheim Investigational Site 87
  - Obihiro, Japan
    - Boehringer Ingelheim Investigational Site 5
  - Oda, Japan
    - Boehringer Ingelheim Investigational Site 255
  - Odai-cho, Japan
    - Boehringer Ingelheim Investigational Site 189
  - Odate, Japan
    - Boehringer Ingelheim Investigational Site 16
  - Odawara, Japan
    - Boehringer Ingelheim Investigational Site 148
  - Ogi, Japan
    - Boehringer Ingelheim Investigational Site 294
  - Oita, Japan
    - Boehringer Ingelheim Investigational Site 286
  - Oita, Japan
    - Boehringer Ingelheim Investigational Site 287
  - Okayama, Japan
    - Boehringer Ingelheim Investigational Site 251
  - Okayama, Japan
    - Boehringer Ingelheim Investigational Site 252
  - Okayama, Japan
    - Boehringer Ingelheim Investigational Site 253
  - Omuta, Japan
    - Boehringer Ingelheim Investigational Site 308
  - Omuta, Japan
    - Boehringer Ingelheim Investigational Site 309
  - Osaka, Japan
    - Boehringer Ingelheim Investigational Site 219
  - Osaka, Japan
    - Boehringer Ingelheim Investigational Site 220
  - Osaka, Japan
    - Boehringer Ingelheim Investigational Site 221
  - Osaka, Japan
    - Boehringer Ingelheim Investigational Site 222
  - Osaka, Japan
    - Boehringer Ingelheim Investigational Site 223
  - Osaka, Japan
    - Boehringer Ingelheim Investigational Site 224
  - Osaka, Japan
    - Boehringer Ingelheim Investigational Site 225
  - Osaka, Japan
    - Boehringer Ingelheim Investigational Site 226
  - Oshu, Japan
    - Boehringer Ingelheim Investigational Site 21
  - Otaru, Japan
    - Boehringer Ingelheim Investigational Site 6
  - Otsu, Japan
    - Boehringer Ingelheim Investigational Site 210
  - Oura-machi, Japan
    - Boehringer Ingelheim Investigational Site 75
  - Oyama, Japan
    - Boehringer Ingelheim Investigational Site 55
  - Sado, Japan
    - Boehringer Ingelheim Investigational Site 67
  - Sagamihara, Japan
    - Boehringer Ingelheim Investigational Site 149
  - Sagamihara, Japan
    - Boehringer Ingelheim Investigational Site 150
  - Saijo, Japan
    - Boehringer Ingelheim Investigational Site 274
  - Saitama, Japan
    - Boehringer Ingelheim Investigational Site 120
  - Saitama, Japan
    - Boehringer Ingelheim Investigational Site 121
  - Saitama, Japan
    - Boehringer Ingelheim Investigational Site 122
  - Sakai, Japan
    - Boehringer Ingelheim Investigational Site 227
  - Sakai, Japan
    - Boehringer Ingelheim Investigational Site 228
  - Sakai, Japan
    - Boehringer Ingelheim Investigational Site 229
  - Sakata, Japan
    - Boehringer Ingelheim Investigational Site 39
  - Sakura, Japan
    - Boehringer Ingelheim Investigational Site 134
  - Sanjo, Japan
    - Boehringer Ingelheim Investigational Site 68
  - Sanmu, Japan
    - Boehringer Ingelheim Investigational Site 135
  - Sanyoonoda, Japan
    - Boehringer Ingelheim Investigational Site 267
  - Sanyoonoda, Japan
    - Boehringer Ingelheim Investigational Site 268
  - Sapporo, Japan
    - Boehringer Ingelheim Investigational Site 8
  - Sapporo, Japan
    - Boehringer Ingelheim Investigational Site 9
  - Sapporo, Japan
    - Boehringer Ingelheim Investigational Site 7
  - Sapporo, Japan
    - Boehringer Ingelheim Investigational Site 10
  - Sapporo, Japan
    - Boehringer Ingelheim Investigational Site 11
  - Sapporo, Japan
    - Boehringer Ingelheim Investigational Site 12
  - Sasebo, Japan
    - Boehringer Ingelheim Investigational Site 298
  - Satte, Japan
    - Boehringer Ingelheim Investigational Site 123
  - Sayama, Japan
    - Boehringer Ingelheim Investigational Site 124
  - Sendai, Japan
    - Boehringer Ingelheim Investigational Site 32
  - Sendai, Japan
    - Boehringer Ingelheim Investigational Site 33
  - Sendai, Japan
    - Boehringer Ingelheim Investigational Site 34
  - Sendai, Japan
    - Boehringer Ingelheim Investigational Site 35
  - Sendai, Japan
    - Boehringer Ingelheim Investigational Site 36
  - Sendai, Japan
    - Boehringer Ingelheim Investigational Site 37
  - Shibata, Japan
    - Boehringer Ingelheim Investigational Site 69
  - Shibetsu, Japan
    - Boehringer Ingelheim Investigational Site 13
  - Shiki, Japan
    - Boehringer Ingelheim Investigational Site 125
  - Shimanto, Japan
    - Boehringer Ingelheim Investigational Site 279
  - Shime-machi, Japan
    - Boehringer Ingelheim Investigational Site 310
  - Shimoda, Japan
    - Boehringer Ingelheim Investigational Site 183
  - Shingu, Japan
    - Boehringer Ingelheim Investigational Site 248
  - Shiraishi, Japan
    - Boehringer Ingelheim Investigational Site 38
  - Shiroi, Japan
    - Boehringer Ingelheim Investigational Site 136
  - Shizuoka, Japan
    - Boehringer Ingelheim Investigational Site 184
  - Shizuoka, Japan
    - Boehringer Ingelheim Investigational Site 185
  - Shunan, Japan
    - Boehringer Ingelheim Investigational Site 269
  - Soka, Japan
    - Boehringer Ingelheim Investigational Site 126
  - Sukagawa, Japan
    - Boehringer Ingelheim Investigational Site 27
  - Suzuka, Japan
    - Boehringer Ingelheim Investigational Site 190
  - Tachikawa, Japan
    - Boehringer Ingelheim Investigational Site 88
  - Takaoka, Japan
    - Boehringer Ingelheim Investigational Site 203
  - Takaoka, Japan
    - Boehringer Ingelheim Investigational Site 204
  - Takarazuka, Japan
    - Boehringer Ingelheim Investigational Site 245
  - Takasaki, Japan
    - Boehringer Ingelheim Investigational Site 76
  - Takasaki, Japan
    - Boehringer Ingelheim Investigational Site 77
  - Takayama, Japan
    - Boehringer Ingelheim Investigational Site 177
  - Tatsuno, Japan
    - Boehringer Ingelheim Investigational Site 246
  - Tokai-mura, Japan
    - Boehringer Ingelheim Investigational Site 47
  - Tokamachi, Japan
    - Boehringer Ingelheim Investigational Site 70
  - Tokoname, Japan
    - Boehringer Ingelheim Investigational Site 170
  - Tokorozawa, Japan
    - Boehringer Ingelheim Investigational Site 127
  - Tokushima, Japan
    - Boehringer Ingelheim Investigational Site 281
  - Tokushima, Japan
    - Boehringer Ingelheim Investigational Site 282
  - Tokyo Adachi-ku, Japan
    - Boehringer Ingelheim Investigational Site 89
  - Tokyo Adachi-ku, Japan
    - Boehringer Ingelheim Investigational Site 90
  - Tokyo Bunkyo-ku, Japan
    - Boehringer Ingelheim Investigational Site 102
  - Tokyo Chiyoda-ku, Japan
    - Boehringer Ingelheim Investigational Site 91
  - Tokyo Chiyoda-ku, Japan
    - Boehringer Ingelheim Investigational Site 92
  - Tokyo Kita-ku, Japan
    - Boehringer Ingelheim Investigational Site 93
  - Tokyo Koto-ku, Japan
    - Boehringer Ingelheim Investigational Site 94
  - Tokyo Meguro-ku, Japan
    - Boehringer Ingelheim Investigational Site 95
  - Tokyo Meguro-ku, Japan
    - Boehringer Ingelheim Investigational Site 96
  - Tokyo Nerima-ku, Japan
    - Boehringer Ingelheim Investigational Site 97
  - Tokyo Ota-ku, Japan
    - Boehringer Ingelheim Investigational Site 98
  - Tokyo Ota-ku, Japan
    - Boehringer Ingelheim Investigational Site 99
  - Tokyo Setagaya-ku, Japan
    - Boehringer Ingelheim Investigational Site 100
  - Tokyo Setagaya-ku, Japan
    - Boehringer Ingelheim Investigational Site 101
  - Tokyo Shibuya-ku, Japan
    - Boehringer Ingelheim Investigational Site 103
  - Tokyo Shinagawa-ku, Japan
    - Boehringer Ingelheim Investigational Site 104
  - Tokyo Shinagawa-ku, Japan
    - Boehringer Ingelheim Investigational Site 105
  - Tokyo Shinagawa-ku, Japan
    - Boehringer Ingelheim Investigational Site 106
  - Tokyo Shinjuku-ku, Japan
    - Boehringer Ingelheim Investigational Site 107
  - Tokyo Suginami-ku, Japan
    - Boehringer Ingelheim Investigational Site 108
  - Tokyo Sumida-ku, Japan
    - Boehringer Ingelheim Investigational Site 109
  - Tokyo Toshima-ku, Japan
    - Boehringer Ingelheim Investigational Site 110
  - Tomakomai, Japan
    - Boehringer Ingelheim Investigational Site 14
  - Tomioka-machi, Japan
    - Boehringer Ingelheim Investigational Site 28
  - Tosu, Japan
    - Boehringer Ingelheim Investigational Site 295
  - Tottori, Japan
    - Boehringer Ingelheim Investigational Site 270
  - Toyako-machi, Japan
    - Boehringer Ingelheim Investigational Site 15
  - Toyama, Japan
    - Boehringer Ingelheim Investigational Site 205
  - Toyohashi, Japan
    - Boehringer Ingelheim Investigational Site 171
  - Toyokawa, Japan
    - Boehringer Ingelheim Investigational Site 172
  - Toyonaka, Japan
    - Boehringer Ingelheim Investigational Site 230
  - Toyota, Japan
    - Boehringer Ingelheim Investigational Site 173
  - Tsuchiura, Japan
    - Boehringer Ingelheim Investigational Site 49
  - Tsuruga, Japan
    - Boehringer Ingelheim Investigational Site 207
  - Tsuruga, Japan
    - Boehringer Ingelheim Investigational Site 208
  - Tsurugi-cho, Japan
    - Boehringer Ingelheim Investigational Site 283
  - Tsuyama, Japan
    - Boehringer Ingelheim Investigational Site 254
  - Ueda, Japan
    - Boehringer Ingelheim Investigational Site 64
  - Uji, Japan
    - Boehringer Ingelheim Investigational Site 201
  - Ushiku, Japan
    - Boehringer Ingelheim Investigational Site 48
  - Utsunomiya, Japan
    - Boehringer Ingelheim Investigational Site 56
  - Utsunomiya, Japan
    - Boehringer Ingelheim Investigational Site 57
  - Uwajima, Japan
    - Boehringer Ingelheim Investigational Site 275
  - Yachimata, Japan
    - Boehringer Ingelheim Investigational Site 137
  - Yaizu, Japan
    - Boehringer Ingelheim Investigational Site 186
  - Yamagata, Japan
    - Boehringer Ingelheim Investigational Site 178
  - Yamato, Japan
    - Boehringer Ingelheim Investigational Site 151
  - Yamatokooriyama, Japan
    - Boehringer Ingelheim Investigational Site 233
  - Yokkaichi, Japan
    - Boehringer Ingelheim Investigational Site 191
  - Yokohama, Japan
    - Boehringer Ingelheim Investigational Site 152
  - Yokohama, Japan
    - Boehringer Ingelheim Investigational Site 153
  - Yokohama, Japan
    - Boehringer Ingelheim Investigational Site 154
  - Yokohama, Japan
    - Boehringer Ingelheim Investigational Site 155
  - Yokohama, Japan
    - Boehringer Ingelheim Investigational Site 156
  - Yokohama, Japan
    - Boehringer Ingelheim Investigational Site 157
  - Yokohama, Japan
    - Boehringer Ingelheim Investigational Site 158
  - Yokosuka, Japan
    - Boehringer Ingelheim Investigational Site 159
  - Yonago, Japan
    - Boehringer Ingelheim Investigational Site 271
  - Yosano-cho, Japan
    - Boehringer Ingelheim Investigational Site 202
  - Yoshika-cho, Japan
    - Boehringer Ingelheim Investigational Site 256
  - Yotsukaido, Japan
    - Boehringer Ingelheim Investigational Site 139
  - Yuki, Japan
    - Boehringer Ingelheim Investigational Site 50
  - Yurihonjo, Japan
    - Boehringer Ingelheim Investigational Site 17

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Child
Adult
Older Adult

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

1000

Description

Inclusion criteria:

Hypertensive patients who have never taken Micombi Tablets.

Exclusion criteria:

None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Micombi® Combination Tablet AP	Drug: Telmisartan 40mg Combination tablet Drug: Hydrochlorothiazide 12.5mg Combination tablet
Micombi® Combination Tablet BP	Drug: Hydrochlorothiazide 12.5mg Combination tablet Drug: Telmisartan 80mg Combination tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Adverse Events (AEs) Time Frame: Week 52	The number of patient with any AEs, patients with drug-related AEs	Week 52

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Systolic Blood Pressure (SBP) Time Frame: Week 0 and Week 52	SBP is observed at Week 0 and Week 52. The change of SBP from Week 0 to Week 52 is calculated.	Week 0 and Week 52
Diastolic Blood Pressure (DBP) Time Frame: Week 0 and Week 52	DBP is observed at Week 0 and Week 52. The change of DBP from Week 0 to Week 52 is calculated.	Week 0 and Week 52
Target Blood Pressure Achievement Rate Time Frame: Week 52	The proportion of the patients with target blood pressure in 52 weeks administrative period. Target blood pressure is defined as 'Guidelines for the management of hypertension (JSH2009)': less than 140/90 (SBP/DBP) mmHg for >= 65 years old or cerebrovascular disorder patient; less than 130/80 in diabetes, chronic kidney disease or myocardial infarction patient; less than 130/85 mmHg for others patient.	Week 52
Blood Pressure Normalised Rate Time Frame: Week 52	The proportion of the patients with normalized blood pressure in 52 weeks on administrative period. Normalized blood pressure is defined less than 140/90 (SBP/DBP) mmHg according to JSH2009	Week 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Collaborators

Astellas Pharma Inc

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Related Info

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2010

Primary Completion (Actual)

December 1, 2011

Study Completion (Actual)

December 1, 2011

Study Registration Dates

First Submitted

December 24, 2009

First Submitted That Met QC Criteria

January 14, 2010

First Posted (Estimate)

January 15, 2010

Study Record Updates

Last Update Posted (Estimate)

May 1, 2014

Last Update Submitted That Met QC Criteria

April 4, 2014

Last Verified

April 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

502.542

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

National Taiwan University Hospital Hsin-Chu Branch

Recruiting

Wearable Blood Pressure Devices to Identify Masked Uncontrolled Hypertension.

Hypertension,Essential | Hypertension, Masked

Taiwan
University of Alabama at Birmingham
Troy University

Completed

Use of Automated Office Blood Pressure Monitoring

Hypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White Coat

United States
Franz Rischard, DO
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Not yet recruiting

Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.

Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)

United States
Abant Izzet Baysal University

Not yet recruiting

The Effect of Self-Acupressure on Blood Pressure, Stress, and Well-Being Levels in Individuals With Hypertension (SAPH)

PRIMARY HYPERTENSION

Turkey (Türkiye)
SingHealth Polyclinics
Nanyang Polytechnic

Enrolling by invitation

Engaging Home-monitored Assessment to Navigate Clinical Decision-making (ENHANCe)

Hypertension,Essential

Singapore
Hacettepe University
Bozok University

Completed

Effects of Different Telerehabilitation Methods In Patients With Hypertension (TELE-HT) (TELE-HT)

Hypertension | Arterial Hypertension | Systemic Hypertension

Turkey (Türkiye)
BackBeat Medical Inc

Not yet recruiting

Clinical Feasibility of Cardiac Neuromodulation Therapy for Heart Failure With Preserved Ejection Fraction

Hypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEF

Georgia
Xuanwu Hospital, Beijing

Not yet recruiting

High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS) for Hypertension: A Randomized Controlled Trial

Primary Hypertension

China
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Not yet recruiting

Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets

Primary Hypertension

China
Instituto de Cardiologia do Rio Grande do Sul

Completed

Chronic Effect of Isometric Exercise on Blood Pressure in Patients With Hypertension

Hypertension (HTN) | Hypertension Arterial

Brazil

Clinical Trials on Telmisartan 40mg

Emory University
National Institute on Aging (NIA)

Completed

Health Evaluation in African Americans Using RAS Therapy (HEART)

Alzheimer's Disease

United States
University of Hawaii
National Institute on Minority Health and Health Disparities (NIMHD)

Terminated

Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients

COVID-19

United States
Yuhan Corporation
Linical Korea

Terminated

A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome

Metabolic Syndrome

Korea, Republic of
Yuhan Corporation

Unknown

HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria

Proteinuria | Chronic Kidney Disease

Korea, Republic of
Kyoto Prefectural University of Medicine

Terminated

Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients (KCPS)

Myocardial Ischemia | Hypertension | Angina Pectoris | Acute Coronary Syndrome | Acute Myocardial Infarction

Japan
Daewoong Pharmaceutical Co. LTD.

Completed

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

Erosive Esophagitis

Korea, Republic of
South China Center For Innovative Pharmaceuticals
Xiangya Hospital of Central South University

Completed

Safety, Tolerability and Pharmacokinetics of AD16 Tablets After MAD in Healthy Chinese Adult Subjects (MAD)

Alzheimer Disease

China
Hanlim Pharm. Co., Ltd.

Completed

Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivikar Tab. 5/40 mg in Healthy Adult Male Subjects

Healthy Male Subjects

Korea, Republic of
Boehringer Ingelheim

Completed

26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension

Hypertension

Australia, Austria, Bulgaria, Czech Republic, Ireland, Italy, New Zealand, Russian Federation, Slovakia, Spain, Ukraine, United Kingdom
Chong Kun Dang Pharmaceutical

Completed

Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin. (CKD-345)

Essential Hypertension | Hyperlipidemia

Korea, Republic of

Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

Post Marketing Surveillance on Long Drug Use of Micombi Combination Tablets in Patients With Hypertension

Study Overview

Status

Conditions

Intervention / Treatment

Study Type

Enrollment (Actual)

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Genders Eligible for Study

Sampling Method

Study Population

Description

Study Plan

How is the study designed?

Design Details

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Collaborators

Publications and helpful links

Helpful Links

Study record dates

Study Major Dates

Study Start

Primary Completion (Actual)

Study Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Estimate)

Study Record Updates

Last Update Posted (Estimate)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Clinical Trials on Hypertension

Clinical Trials on Telmisartan 40mg

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations